What Is Prader Willi Syndrome Market Share?

By Author: haven smith
Total Articles: 196
Comment this article

About Prader–Willi syndrome Market

Intranasal carbetocin is similar to the naturally-occurring hormone oxytocin, but with greater selectivity for the effect of interest stimulation of oxytocin receptors. These receptors are involved in the regulation of both social-emotional and feeding behaviors.

It is approved in over 90 countries outside the United States for the prevention of uterine atony and excessive bleeding during cesarean section delivery. In a press release, Levo Therapeutics stated that the phase 3 study achieved statistical significance with the secondary endpoint evaluating the 3.2 mg dose

However, the study did not meet its primary endpoint evaluating the 9.6 mg dose of LV-101. Enrollment for the study was closed early due to COVID-19, with 119 evaluable patients in the primary analysis set.

Harmony Biosciences intends to commence Phase 2 clinical trial, which was postponed April due to COVID-19, to evaluate pitolisant for the treatment of EDS and other vital symptoms in patients with PWS in the second ...
... half of 2020, with topline results expected in the first half of 2022.

Pitolisant enhances the activity of histaminergic neurons, a type of nerve cell that helps fight uncontrollable sleepiness or narcolepsy. It works by blocking the histamine 3 (H3) receptor, increasing the production and release of histamine, a neurotransmitter that regulates the sleep-wake system, and promotes wakefulness.

The therapy was approved by the US Food and Drug Administration in August 2019, under the brand name Wakix, to treat excessive daytime sleepiness in adults with narcolepsy.

Read More @ Prader–Willi syndrome Market Report